Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SHR-1316 plus chemotherapy versus placebo plus chemotherapy in resectable non-small cell lung cancer
CTR20200587Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Jul 2020; status: active.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200587.